Literature DB >> 28801359

CCR7 Deficiency Allows Accelerated Clearance of Chlamydia from the Female Reproductive Tract.

Lin-Xi Li1, Jasmine C Labuda2, Denise M Imai3, Stephen M Griffey3, Stephen J McSorley2.   

Abstract

Immune mechanisms responsible for pathogen clearance from the female reproductive tract (FRT) are incompletely defined; in particular, the contribution of lymphocyte trafficking to this process is unclear. CCR7-deficient mice have profoundly altered lymphocyte recirculation and display ectopic formation of lymphocyte aggregates within mucosal nonlymphoid tissues, including the FRT. In this study, we investigated how altered lymphocyte distribution in CCR7-deficient mice would affect host responses to Chlamydia muridarum within the reproductive tract. As expected, CCR7-deficient mice exhibited reduced lymphocyte trafficking to lymph nodes and a corresponding increase in T cell populations within the FRT. After intravaginal infection with Chlamydia, CCR7-deficient mice displayed markedly reduced Ag-specific CD4 T cell responses within the local draining iliac lymph nodes, yet robust Th1 and Th17 responses were prominent in the FRT. In addition, Chlamydia-specific Ab responses were dysregulated in CCR7-deficient mice, displaying an unexpected increase in the systemic IgA responses. Importantly, prominent mucosal immune responses in CCR7-deficient mice increased the efficiency of bacteria clearance from the FRT while reducing tissue-associated inflammation and pathology. Thus, increased numbers of lymphocytes within the FRT result in pathogen clearance with reduced immune-mediated pathology.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28801359      PMCID: PMC5605455          DOI: 10.4049/jimmunol.1601314

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Antigen-specific CD8+ T cells respond to Chlamydia trachomatis in the genital mucosa.

Authors:  Nadia R Roan; Michael N Starnbach
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Impact of CCR7 on priming and distribution of antiviral effector and memory CTL.

Authors:  Tobias Junt; Elke Scandella; Reinhold Förster; Philippe Krebs; Stefan Krautwald; Martin Lipp; Hans Hengartner; Burkhard Ludewig
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

3.  Dendritic cell-independent B cell activation during acute virus infection: a role for early CCR7-driven B-T helper cell collaboration.

Authors:  Elke Scandella; Katja Fink; Tobias Junt; Beatrice M Senn; Evelyn Lattmann; Reinhold Förster; Hans Hengartner; Burkhard Ludewig
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

4.  Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells.

Authors:  S G Morrison; R P Morrison
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  In Vivo and Ex Vivo Imaging Reveals a Long-Lasting Chlamydial Infection in the Mouse Gastrointestinal Tract following Genital Tract Inoculation.

Authors:  Qi Zhang; Yumeng Huang; Siqi Gong; Zhangsheng Yang; Xin Sun; Robert Schenken; Guangming Zhong
Journal:  Infect Immun       Date:  2015-06-22       Impact factor: 3.441

6.  In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection.

Authors:  S G Morrison; R P Morrison
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Prevalence of chlamydial and gonococcal infections among young adults in the United States.

Authors:  William C Miller; Carol A Ford; Martina Morris; Mark S Handcock; John L Schmitz; Marcia M Hobbs; Myron S Cohen; Kathleen Mullan Harris; J Richard Udry
Journal:  JAMA       Date:  2004-05-12       Impact factor: 56.272

Review 8.  Development status and future prospects for a vaccine against Chlamydia trachomatis infection.

Authors:  Louise M Hafner; David P Wilson; Peter Timms
Journal:  Vaccine       Date:  2013-08-22       Impact factor: 3.641

9.  CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells.

Authors:  Martin A Schneider; Josef G Meingassner; Martin Lipp; Henrietta D Moore; Antal Rot
Journal:  J Exp Med       Date:  2007-03-19       Impact factor: 14.307

10.  CXCL12 mediates CCR7-independent homing of central memory cells, but not naive T cells, in peripheral lymph nodes.

Authors:  M Lucila Scimone; Thomas W Felbinger; Irina B Mazo; Jens V Stein; Ulrich H Von Andrian; Wolfgang Weninger
Journal:  J Exp Med       Date:  2004-04-19       Impact factor: 14.307

View more
  5 in total

1.  Unexpected Role of CD8 T Cells in Accelerated Clearance of Salmonella enterica Serovar Typhimurium from H-2 Congenic mice.

Authors:  Jasmine C Labuda; Claire E Depew; Oanh H Pham; Joseph M Benoun; Nora A Ramirez; Stephen J McSorley
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

2.  Antibody, but not B-cell-dependent antigen presentation, plays an essential role in preventing Chlamydia systemic dissemination in mice.

Authors:  Priyangi A Malaviarachchi; Miguel A B Mercado; Stephen J McSorley; Lin-Xi Li
Journal:  Eur J Immunol       Date:  2020-03-12       Impact factor: 5.532

3.  B Cell Presentation of Chlamydia Antigen Selects Out Protective CD4γ13 T Cells: Implications for Genital Tract Tissue-Resident Memory Lymphocyte Clusters.

Authors:  Raymond M Johnson; Hong Yu; Norma Olivares Strank; Karuna Karunakaran; Ying Zhu; Robert C Brunham
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

4.  2017: beginning of a new era for Chlamydia research in China and the rest of the world.

Authors:  Huizhou Fan; Guangming Zhong
Journal:  Microbes Infect       Date:  2017-10-06       Impact factor: 2.700

Review 5.  Immunopathogenesis of genital Chlamydia infection: insights from mouse models.

Authors:  Jacob Dockterman; Jörn Coers
Journal:  Pathog Dis       Date:  2021-03-31       Impact factor: 3.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.